Literature DB >> 872500

Physiologic disposition of nabilone, a cannabinol derivative, in man.

A Rubin, L Lemberger, P Warrick, R E Crabtree, H Sullivan, H Rowe, B D Obermeyer.   

Abstract

Nabilone is a cannabinoid that is being evaluated in man as a potentially useful psychoactive drug. We found that nabilone was readily absorbed from the human gastrointestinal tract when administered orally as a coprecipitate with polyvinyl-pyrrolidone. The absorbed drug disappeared from plasma rather rapidly (half-life, approximately 2 hr), evidently due to extensive tissue distribution and rapid metabolism. The metabolites of nabilone persist in plasma for extended periods (half-life of total radioactivity exceeds 20 hr). Circulating metabolites include isomeric carbinols formed by reduction of the ketone in the 9-position of nabilone. Nabilone is eliminated in feces (about 65% of dose) and urine (20%). The excretory products in urine have not been identified, but metabolites that are labile to hydrolysis by beta-glucuronidase or sulfatase do not appear to be formed in significant amounts. A metabolite of nabilone in feces has been identified as a diol formed by reduction of the 9-keto group plus oxidation at the penultimate carbon of the dimethylheptyl side chain. The long duration of action of nabilone in the face of rapid and extensive metabolic elimination suggests that the pharmacologic effects, at least in part, may be exerted by one or more active metabolites.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 872500     DOI: 10.1002/cpt197722185

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

Review 1.  Pharmacokinetic optimisation of antiemetic therapy.

Authors:  M Campbell; D N Bateman
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

2.  Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease.

Authors:  Sean J Udow; Maria Eliza Freitas; Susan H Fox; Anthony E Lang
Journal:  CMAJ       Date:  2018-01-15       Impact factor: 8.262

3.  Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial.

Authors:  Jörg Wissel; Tanja Haydn; Jörg Müller; Christian Brenneis; Thomas Berger; Werner Poewe; Ludwig D Schelosky
Journal:  J Neurol       Date:  2006-09-20       Impact factor: 4.849

4.  Microbiological transformations of nabilone, a synthetic cannabinoid.

Authors:  R A Archer; D S Fukuda; A D Kossoy; B J Abbott
Journal:  Appl Environ Microbiol       Date:  1979-05       Impact factor: 4.792

Review 5.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Nabilone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  A Ward; B Holmes
Journal:  Drugs       Date:  1985-08       Impact factor: 9.546

7.  Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse.

Authors:  Margaret Haney; Ziva D Cooper; Gillinder Bedi; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin
Journal:  Neuropsychopharmacology       Date:  2013-02-26       Impact factor: 7.853

8.  Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study.

Authors:  B Frank; M G Serpell; J Hughes; J N S Matthews; D Kapur
Journal:  BMJ       Date:  2008-01-08

9.  A Case Report on Cannabinoid Hyperemesis Syndrome in Palliative Care: How Good Intentions Can Go Wrong.

Authors:  Helen Senderovich; Sarah Waicus
Journal:  Oncol Res Treat       Date:  2022-05-03       Impact factor: 2.844

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.